Enliven Therapeutics(US:ELVN)2025-05-14 20:10Financial Performance - Enliven Therapeutics reported a net loss of $28.5 million for Q1 2025, compared to a net loss of $22.7 million for Q1 2024, reflecting an increase in losses of approximately 25% year-over-year[7] - Total operating expenses for Q1 2025 were $31.7 million, compared to $26.0 million for Q1 2024, representing a 22.1% increase[12] - Enliven's stockholders' equity decreased to $288.3 million as of March 31, 2025, down from $309.8 million at the end of 2024[12] Research and Development - Research and development expenses for Q1 2025 were $24.9 million, up from $20.0 million in Q1 2024, indicating a 24.5% increase[7] - Enliven plans to explore strategic alternatives for the ELVN-002 program and does not intend to pursue its development beyond 2025[7] - The company is preparing for a potential pivotal trial for ELVN-001 in 2026, focusing on clinical execution for the remainder of the year[2] Clinical Trials - In the Phase 1 ENABLE clinical trial of ELVN-001, 44% of evaluable patients achieved major molecular response (MMR) by 24 weeks, with 100% of those who achieved MMR maintaining it[3] - The median treatment duration for patients in the ELVN-001 trial was approximately 26 weeks, with 82% of patients remaining on study[3] - The first patient in the Phase 1 exploratory cohort evaluating ELVN-002 in combination with trastuzumab deruxtecan has been dosed, indicating progress in the clinical pipeline[7] Cash Position - The company had cash, cash equivalents, and marketable securities totaling $289.6 million as of March 31, 2025, expected to provide a cash runway into late 2027[7]